Emergent BioSolutions GC gets 46,702 stock options

Emergent BioSolutions Inc. reported insider equity activity by SVP and General Counsel Jessica Perl.

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported insider equity activity by SVP and General Counsel Jessica Perl. She received a grant of 46,702 employee stock options at an exercise price of $0.00 per option on common stock. According to a footnote, these options vest in three equal installments beginning on the day prior to the anniversary date of the grant.

On a separate date, 6,465 shares of common stock were disposed of in a tax-withholding disposition at $8.44 per share, with a footnote explaining the shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units. Following these transactions, Perl directly owned 61,004 common shares and held 142,647 stock options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Perl Jessica

Role SVP, General Counsel, Corp Sec

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	6,465	$8.44	$55K
Grant/Award	Employee Stock Option (Right to buy)	46,702	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to buy) — 142,647 contracts (Direct); Common Stock — 61,004 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
2. F2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Emergent BioSolutions (EBS) report for Jessica Perl?

Emergent BioSolutions reported that SVP and General Counsel Jessica Perl received a 46,702-share stock option grant and had 6,465 common shares withheld for taxes upon restricted stock unit vesting, according to the Form 4 insider filing.

Was the Emergent BioSolutions (EBS) insider transaction a sale on the open market?

The Form 4 shows a tax-withholding disposition of 6,465 shares at $8.44 per share, with a footnote stating the shares were withheld to pay taxes on restricted stock unit vesting, not an open-market sale.

What stock option grant did Jessica Perl receive at Emergent BioSolutions (EBS)?

Jessica Perl received an employee stock option grant covering 46,702 shares of Emergent BioSolutions common stock at an exercise price of $0.00 per option, vesting in three equal installments beginning just before each anniversary of the grant date.

How many Emergent BioSolutions (EBS) shares does Jessica Perl hold after these transactions?

After the reported transactions, Jessica Perl directly owned 61,004 shares of Emergent BioSolutions common stock and held 142,647 employee stock options, as disclosed in the Form 4 ownership totals following the grant and tax-withholding disposition.

What does the vesting schedule for Jessica Perl’s new EBS stock options look like?

The footnote states that the 46,702-share stock option grant vests in three equal installments, with vesting beginning on the day prior to the anniversary date of the grant and continuing annually in equal portions thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 09:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perl Jessica

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel, Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		F		6,465(1)	D	$8.44	61,004	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		46,702		(2)	03/02/2033	Common Stock	46,702	$0	142,647	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.